Federal University of São Paulo

unifesp.br

Total trials

432

Active

25

Phase 3

49

Total enrollment

100,902

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 18 of 18 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Platelet-rich fibrin2
Triple combination formula1
Bimatoprost .03% sterile ophthalmic solution1
Corticosteroid1
Midazolam2
Ketamine2
Gammora®1
Erythropoietin1
Maraviroc2
Dolutegravir2
Dendritic Cell Vaccine2
Auranofin2
Sirtuin Histone deacetylase inhibitor2
Tenofovir Disoproxil1
Chemical Denervation with Absolute Alcohol1
Promestriene1
Bone Marrow Aspirate1
Estriol1

Next readouts

  • 2024-12-10
  • 2024-12-31
  • 2025-06-01
  • 2025-08
  • 2025-09
  • 2025-09-15
  • 2026-07-01
  • 2026-09
  • 2027-02-01
  • 2027-06-01

Top conditions

  • Obesity13
  • Fibromyalgia11
  • Rheumatoid Arthritis10
  • Pain10
  • Knee Osteoarthritis8
  • Inflammation7
  • Physical Activity6
  • Chronic Low Back Pain5

Frequently asked questions about Federal University of São Paulo

How many clinical trials does Federal University of São Paulo have on ClinicalTrials.gov?
Federal University of São Paulo is listed as the lead sponsor on 432 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
How many of Federal University of São Paulo's trials are in Phase 3?
49 of Federal University of São Paulo's trials are in Phase 3, spread across 18 active drug programs.
What therapeutic areas does Federal University of São Paulo focus on?
Federal University of São Paulo's most-studied conditions on ClinicalTrials.gov are Obesity, Fibromyalgia, Rheumatoid Arthritis, Pain, Knee Osteoarthritis.
When are Federal University of São Paulo's next clinical trial readouts?
Federal University of São Paulo has 10 upcoming primary-completion readouts tracked here; the soonest is “Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma”, expected around 2024-12-10.